Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat with Fulvestrant in Advanced Breast Cancer
NCT02115594Phase 2Withdrawn
- Sponsor
- Syndax Pharmaceuticals
- Start
- Apr 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of entinostat in breast cancer, sponsored by Syndax Pharmaceuticals. Planned start Apr 2014; status: withdrawn.
02
Drugs
entinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02115594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02115594.